



## ***Modular Program Report***

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at [info@mini-sentinel.org](mailto:info@mini-sentinel.org).

## Overview

**Request Description** FDA has requested execution of Modular Program #1 (MP1) to investigate the use of the following oral antifungal medications: fluconazole, itraconazole, ketoconazole, posaconazole, terbinafine, and voriconazo. The query consisted of 12 runs (one for each year/period) and was run against the Mini-Sentinel Distributed Database (MSDD). The query was distributed to 17 Data Partners on December 9, 2011.

Results provide counts of prevalent and incident users, dispensings, and total days supplied. A user was considered a new user if he/she was not exposed to the drug of interest in the prior drug washout period (90 days). The query period for the request was January 1, 2000 to December 31, 2010.

**Request ID** msy3\_mpr1

**Specifications** Program parameter inputs and scenarios

**Glossary** List of terms found in this report and their definitions

**Table 1a** Table displaying the number of prevalent users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2000 - December 31, 2010

**Figure 1a** Two figures displaying the information in the prior tab.

**Table 1b** Table displaying the number of prevalent users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2000 - December 31, 2010

**Figure 2b** Two figures displaying the information in the prior tab.

**Table 2a** Table displaying the number of prevalent users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2000 - December 31, 2010

**Table 2b** Table displaying the number of incident users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2000 - December 31, 2010

**Table 3a** Table displaying the number of prevalent users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2000 - December 31, 2010

**Table 3b** Table displaying the number of incident users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2000 - December 31, 2010

**Table 4a** Table displaying the number of prevalent users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2000 - December 31, 2010

**Table 4b** Table displaying the number of incident users, dispensings, total days supplied, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2000 - December 31, 2010

**Notes:** Please contact the Mini-Sentinel Operations Center (MSOC\_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

### MSY3MPR1 Specifications

Modular Program #1 (MP1) was used to investigate use of the following oral antifungal medications: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Terbinafine, and Voriconazole. The query consisted of 12 runs (one for each year/period) and was run against the Mini-Sentinel Distributed Database. The time window for the request was January 1, 2000 through December 31, 2010. Age groups were split as follows: 0-18 19-50 51-64 65+. In total, six different scenarios were examined in this report with differing exposures of interest. See below for a description of each of these scenarios.

Scenario	Drug/Exposure Criteria			
	Prevalent/Incident exposure	Incident w/ respect to (incidence criteria):	Washout (days)	Washout type*
1	Fluconazole	Fluconazole	90	MULT
2	Itraconazole	Itraconazole	90	MULT
3	Ketoconazole	Ketoconazole	90	MULT
4	Posaconazole	Posaconazole	90	MULT
5	Terbinafine	Terbinafine	90	MULT
6	Voriconazole	Voriconazole	90	MULT

\*A "MULT" washout type for the exposure will consider all dispensings for each member that meet the 183 washout period. There can be more than one incident dispensing per member. The enrollment requirement is based on the number of days in the washout.

\*\*Modular Program 1 will consider those members with at least drug coverage.

## Glossary of Terms in Modular Program 1\*

**Eligible Members (incidence-based cohort)** - Number of members eligible for incident exposure (defined by the washout period) with drug and medical coverage during the query period.

**Eligible Members (prevalence-based cohort)** - Number of members with at least one day of drug and medical coverage\*\* during the query

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled”

**Member-Days (incidence-based cohort)** - Sum of all days of enrollment with medical and drug coverage\*\* in the query period preceded by

**Member-Days (prevalence-based cohort)** - Sum of all days members are enrolled with drug and medical coverage\*\* during the query

**New Starts**- Number of incident exposures during the query period. User must have no prior exposures in the washout period. For a minimum washout type, an individual may have no more than one new start. For a multiple washout type, an individual may have more

**New Users** - Number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

**Query Period** - period in which the modular program looks for exposures of interest.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage.

\*all terms may not be used in this report

\*\*in cases where only NDCs are used to identify exposure, only drug coverage is required

**Table 1a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug Product**

	<b>Users</b>	<b>Dispensings</b>	<b>Total Days Supplied</b>	<b>Days Supplied/ User</b>	<b>Dispensings/ User</b>	<b>Days Supplied/ Dispensing</b>
Fluconazole	3,927,143	8,986,038	64,738,351	16.48	2.29	7.20
Itraconazole	63,616	187,719	4,161,844	65.42	2.95	22.17
Ketoconazole	321,796	552,614	9,655,413	30.00	1.72	17.47
Posaconazole	1,840	7,312	157,386	85.54	3.97	21.52
Terbinafine	537,243	1,282,598	39,033,004	72.65	2.39	30.43
Voriconazole	11,121	47,020	1,216,564	109.39	4.23	25.87

Figure 1a1. Number of Prevalent Users and Dispensings between January 1, 2000 and December 31, 2010, by Drug Product





Figure 1a2. Prevalent Users per Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing between January 1, 2000 and December 31, 2010, by Drug Product




**Table 1b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug Product**


	<b>Users</b>	<b>Dispensings</b>	<b>Total Days Supplied</b>	<b>Days Supplied/ User</b>	<b>Dispensings/ User</b>	<b>Days Supplied/ Dispensing</b>
Fluconazole	3,270,426	7,054,089	48,505,004	14.83	2.16	6.88
Itraconazole	46,261	128,444	2,777,929	60.05	2.78	21.63
Ketoconazole	263,949	436,063	7,365,677	27.91	1.65	16.89
Posaconazole	861	3,291	71,491	83.03	3.82	21.72
Terbinafine	446,738	1,061,932	32,545,170	72.85	2.38	30.65
Voriconazole	6,643	25,847	659,038	99.21	3.89	25.50



Figure 1a1. Number of Prevalent Users and Dispensings between January 1, 2004 and December 31, 2011, by Drug Product



**Figure 1a2. Prevalent Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing between January 1, 2004 and December 31, 2011, by Drug Product**



**Table 2a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
0 to 18 years	270,690	492,081	3,630,893	13.41	1.82	7.38
19 to 50 years	2,534,577	6,081,355	38,162,313	15.06	2.40	6.28
51 to 64 years	636,596	1,496,860	13,563,159	21.31	2.35	9.06
65+ years	485,280	915,742	9,381,986	19.33	1.89	10.25
<b>Itraconazole</b>						
0 to 18 years	4,064	10,331	249,219	61.32	2.54	24.12
19 to 50 years	33,840	97,726	2,053,357	60.68	2.89	21.01
51 to 64 years	16,910	54,705	1,267,984	74.98	3.24	23.18
65+ years	8,802	24,957	591,284	67.18	2.84	23.69
<b>Ketoconazole</b>						
0 to 18 years	29,381	44,631	653,724	22.25	1.52	14.65
19 to 50 years	207,252	335,784	5,219,746	25.19	1.62	15.54
51 to 64 years	52,006	98,273	1,936,569	37.24	1.89	19.71
65+ years	33,157	73,926	1,845,374	55.66	2.23	24.96
<b>Posaconazole</b>						
0 to 18 years	78	353	7,998	102.54	4.53	22.66
19 to 50 years	700	2,757	61,366	87.67	3.94	22.26
51 to 64 years	692	2,747	60,359	87.22	3.97	21.97
65+ years	370	1,455	27,663	74.76	3.93	19.01
<b>Terbinafine</b>						
0 to 18 years	19,235	34,625	990,794	51.51	1.80	28.61
19 to 50 years	281,567	669,693	19,838,744	70.46	2.38	29.62
51 to 64 years	145,130	380,338	11,762,414	81.05	2.62	30.93
65+ years	91,311	197,942	6,441,052	70.54	2.17	32.54
<b>Voriconazole</b>						
0 to 18 years	912	4,518	108,543	119.02	4.95	24.02
19 to 50 years	3,690	16,468	434,311	117.70	4.46	26.37
51 to 64 years	3,713	16,781	457,426	123.20	4.52	27.26
65+ years	2,806	9,253	216,284	77.08	3.30	23.37

**Table 2b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
0 to 18 years	220,625	402,922	2,732,489	12.39	1.83	6.78
19 to 50 years	2,081,040	4,717,153	28,350,654	13.62	2.27	6.01
51 to 64 years	545,988	1,181,202	10,135,820	18.56	2.16	8.58
65+ years	422,773	752,812	7,286,041	17.23	1.78	9.68
<b>Itraconazole</b>						
0 to 18 years	3,198	7,698	179,155	56.02	2.41	23.27
19 to 50 years	24,175	65,795	1,353,918	56.00	2.72	20.58
51 to 64 years	12,437	37,862	851,181	68.44	3.04	22.48
65+ years	6,451	17,089	393,675	61.03	2.65	23.04
<b>Ketoconazole</b>						
0 to 18 years	25,751	38,179	541,029	21.01	1.48	14.17
19 to 50 years	168,219	264,869	4,001,642	23.79	1.57	15.11
51 to 64 years	43,241	77,565	1,475,568	34.12	1.79	19.02
65+ years	26,738	55,450	1,347,438	50.39	2.07	24.30
<b>Posaconazole</b>						
0 to 18 years	36	182	3,890	108.06	5.06	21.37
19 to 50 years	312	1,112	25,274	81.01	3.56	22.73
51 to 64 years	335	1,408	31,443	93.86	4.20	22.33
65+ years	178	589	10,884	61.15	3.31	18.48
<b>Terbinafine</b>						
0 to 18 years	16,608	29,685	856,323	51.56	1.79	28.85
19 to 50 years	229,459	544,936	16,248,780	70.81	2.37	29.82
51 to 64 years	122,588	319,160	9,914,497	80.88	2.60	31.06
65+ years	78,083	168,151	5,525,570	70.77	2.15	32.86
<b>Voriconazole</b>						
0 to 18 years	594	2,796	64,748	109.00	4.71	23.16
19 to 50 years	1,987	7,952	209,031	105.20	4.00	26.29
51 to 64 years	2,262	9,572	259,304	114.63	4.23	27.09
65+ years	1,800	5,527	125,955	69.98	3.07	22.79

**Table 3a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Sex**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
Female	3,504,263	8,146,420	50,275,429	14.35	2.32	6.17
Male	418,297	830,166	14,417,029	34.47	1.98	17.37
Unknown	4,581	9,449	45,882	10.02	2.06	4.86
<b>Itraconazole</b>						
Female	31,897	89,463	1,946,290	61.02	2.80	21.76
Male	31,643	98,069	2,211,783	69.90	3.10	22.55
Unknown	76	187	3,771	49.62	2.46	20.17
<b>Ketoconazole</b>						
Female	146,243	238,753	3,968,993	27.14	1.63	16.62
Male	175,222	313,375	5,679,009	32.41	1.79	18.12
Unknown	331	486	7,411	22.39	1.47	15.25
<b>Posaconazole</b>						
Female	792	2,908	61,168	77.23	3.67	21.03
Male	1,044	4,396	96,039	91.99	4.21	21.85
Unknown	4	8	179	44.75	2.00	22.38
<b>Terbinafine</b>						
Female	263,069	624,105	19,084,762	72.55	2.37	30.58
Male	273,744	657,499	19,920,903	72.77	2.40	30.30
Unknown	430	994	27,339	63.58	2.31	27.50
<b>Voriconazole</b>						
Female	5,160	20,765	532,359	103.17	4.02	25.64
Male	5,949	26,202	682,995	114.81	4.40	26.07
Unknown	12	53	1,210	100.83	4.42	22.83

**Table 3b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Sex**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
Female	2,916,016	6,394,835	37,755,682	12.95	2.19	5.90
Male	350,604	651,718	10,713,921	30.56	1.86	16.44
Unknown	3,804	7,533	35,390	9.30	1.98	4.70
<b>Itraconazole</b>						
Female	22,699	60,704	1,298,667	57.21	2.67	21.39
Male	23,510	67,623	1,476,867	62.82	2.88	21.84
Unknown	52	117	2,395	46.06	2.25	20.47
<b>Ketoconazole</b>						
Female	116,298	182,007	2,917,397	25.09	1.57	16.03
Male	147,378	253,665	4,442,458	30.14	1.72	17.51
Unknown	273	391	5,822	21.33	1.43	14.89
<b>Posaconazole</b>						
Female	353	1,250	27,463	77.80	3.54	21.97
Male	505	2,036	43,879	86.89	4.03	21.55
Unknown	3	5	149	49.67	1.67	29.80
<b>Terbinafine</b>						
Female	216,782	512,950	15,817,828	72.97	2.37	30.84
Male	229,596	548,168	16,704,890	72.76	2.39	30.47
Unknown	360	814	22,452	62.37	2.26	27.58
<b>Voriconazole</b>						
Female	3,057	11,198	284,277	92.99	3.66	25.39
Male	3,580	14,635	374,521	104.61	4.09	25.59
Unknown	6	14	240	40.00	2.33	17.14

**Table 4a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
2000	97,141	155,748	1,226,057	12.62	1.60	7.87
2001	132,265	214,615	1,511,880	11.43	1.62	7.04
2002	154,100	256,054	1,626,737	10.56	1.66	6.35
2003	163,825	270,663	1,710,678	10.44	1.65	6.32
2004	474,031	790,399	3,951,389	8.34	1.67	5.00
2005	501,412	852,864	4,545,812	9.07	1.70	5.33
2006	538,225	904,175	5,033,484	9.35	1.68	5.57
2007	670,578	1,084,835	7,589,750	11.32	1.62	7.00
2008	949,164	1,517,358	13,892,981	14.64	1.60	9.16
2009	937,602	1,500,152	12,332,706	13.15	1.60	8.22
2010	922,455	1,468,703	11,610,481	12.59	1.59	7.91
<b>Itraconazole</b>						
2000	3,758	8,873	203,718	54.21	2.36	22.96
2001	3,348	8,285	190,496	56.90	2.47	22.99
2002	3,061	7,794	175,299	57.27	2.55	22.49
2003	2,913	7,301	168,269	57.76	2.51	23.05
2004	11,171	25,474	509,978	45.65	2.28	20.02
2005	9,599	23,045	466,496	48.60	2.40	20.24
2006	8,306	20,160	424,734	51.14	2.43	21.07
2007	7,855	19,606	442,149	56.29	2.50	22.55
2008	10,484	25,202	583,266	55.63	2.40	23.14
2009	9,399	22,696	529,699	56.36	2.41	23.34
2010	8,373	19,835	483,276	57.72	2.37	24.36

**Table 4a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ketoconazole</b>						
2000	11,481	15,930	287,898	25.08	1.39	18.07
2001	11,892	16,522	292,046	24.56	1.39	17.68
2002	13,410	18,762	327,803	24.44	1.40	17.47
2003	13,316	18,479	323,947	24.33	1.39	17.53
2004	39,095	55,667	948,536	24.26	1.42	17.04
2005	39,026	54,786	929,618	23.82	1.40	16.97
2006	40,609	56,521	977,992	24.08	1.39	17.30
2007	46,780	67,168	1,208,337	25.83	1.44	17.99
2008	64,206	91,460	1,617,336	25.19	1.42	17.68
2009	58,529	82,317	1,423,163	24.32	1.41	17.29
2010	54,023	75,806	1,336,511	24.74	1.40	17.63
<b>Posaconazole</b>						
2000	0	0	0	---	---	---
2001	0	0	0	---	---	---
2002	0	0	0	---	---	---
2003	0	0	0	---	---	---
2004	0	0	0	---	---	---
2005	0	0	0	---	---	---
2006	42	74	1,458	34.71	1.76	19.70
2007	405	1,128	24,101	59.51	2.79	21.37
2008	651	2,070	44,103	67.75	3.18	21.31
2009	645	2,108	43,741	67.82	3.27	20.75
2010	593	1,938	44,048	74.28	3.27	22.73



**Table 4a. Summary of Prevalent Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Terbinafine</b>						
2000	15,225	29,695	839,920	55.17	1.95	28.28
2001	14,914	30,251	831,211	55.73	2.03	27.48
2002	14,095	28,100	799,449	56.72	1.99	28.45
2003	16,344	32,757	961,115	58.81	2.00	29.34
2004	74,764	163,127	4,669,403	62.46	2.18	28.62
2005	74,887	161,466	4,626,073	61.77	2.16	28.65
2006	73,100	156,881	4,575,010	62.59	2.15	29.16
2007	63,838	133,168	3,970,125	62.19	2.09	29.81
2008	95,532	193,442	6,076,355	63.61	2.02	31.41
2009	98,013	185,846	6,060,612	61.83	1.90	32.61
2010	92,529	169,045	5,663,318	61.21	1.83	33.50
<b>Voriconazole</b>						
2000	0	0	0	---	---	---
2001	0	0	0	---	---	---
2002	88	192	4,426	50.30	2.18	23.05
2003	309	1,013	25,785	83.45	3.28	25.45
2004	1,017	3,321	85,420	83.99	3.27	25.72
2005	1,195	3,794	96,684	80.91	3.17	25.48
2006	1,416	4,614	117,878	83.25	3.26	25.55
2007	2,115	6,831	176,751	83.57	3.23	25.87
2008	3,042	10,175	260,970	85.79	3.34	25.65
2009	2,643	8,917	230,940	87.38	3.37	25.90
2010	2,608	8,496	225,263	86.37	3.26	26.51

**Table 4b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Fluconazole</b>						
2000	75,152	114,469	784,026	10.43	1.52	6.85
2001	118,403	179,071	1,116,402	9.43	1.51	6.23
2002	137,095	210,569	1,203,261	8.78	1.54	5.71
2003	145,236	220,741	1,263,700	8.70	1.52	5.72
2004	339,877	506,238	2,349,776	6.91	1.49	4.64
2005	429,076	676,249	3,291,936	7.67	1.58	4.87
2006	453,768	705,618	3,568,774	7.86	1.56	5.06
2007	539,124	810,848	4,867,290	9.03	1.50	6.00
2008	766,820	1,131,108	9,416,599	12.28	1.48	8.33
2009	817,164	1,222,312	9,496,084	11.62	1.50	7.77
2010	797,018	1,183,904	8,796,401	11.04	1.49	7.43
<b>Itraconazole</b>						
2000	2,520	5,846	129,993	51.58	2.32	22.24
2001	2,492	5,187	113,020	45.35	2.08	21.79
2002	2,206	4,694	96,219	43.62	2.13	20.50
2003	2,134	4,479	94,863	44.45	2.10	21.18
2004	6,496	13,078	251,544	38.72	2.01	19.23
2005	6,935	14,985	286,251	41.28	2.16	19.10
2006	5,801	12,847	261,770	45.12	2.21	20.38
2007	5,160	11,442	242,065	46.91	2.22	21.16
2008	6,653	14,087	305,713	45.95	2.12	21.70
2009	6,633	14,120	316,363	47.70	2.13	22.41
2010	5,771	11,995	282,992	49.04	2.08	23.59

**Table 4b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ketoconazole</b>						
2000	8,686	11,634	201,051	23.15	1.34	17.28
2001	10,363	13,441	220,316	21.26	1.30	16.39
2002	11,630	15,115	246,106	21.16	1.30	16.28
2003	11,566	14,800	239,411	20.70	1.28	16.18
2004	28,416	36,885	578,875	20.37	1.30	15.69
2005	32,890	43,580	695,626	21.15	1.33	15.96
2006	33,949	44,699	725,033	21.36	1.32	16.22
2007	36,618	48,630	798,034	21.79	1.33	16.41
2008	51,084	67,217	1,100,981	21.55	1.32	16.38
2009	49,789	65,230	1,041,145	20.91	1.31	15.96
2010	45,708	59,500	971,347	21.25	1.30	16.33
<b>Posaconazole</b>						
2000	0	0	0	---	---	---
2001	0	0	0	---	---	---
2002	0	0	0	---	---	---
2003	0	0	0	---	---	---
2004	0	0	0	---	---	---
2005	0	0	0	---	---	---
2006	24	37	781	32.54	1.54	21.11
2007	168	445	9,759	58.09	2.65	21.93
2008	254	665	13,231	52.09	2.62	19.90
2009	295	802	16,004	54.25	2.72	19.96
2010	247	656	14,501	58.71	2.66	22.11

**Table 4b. Summary of Incident Drug Use in the MSDD between January 1, 2000 and December 31, 2010, by Drug and Year**

	Users	Dispensings	Total Days Supplied	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Terbinafine</b>						
2000	11,253	21,944	620,199	55.11	1.95	28.26
2001	12,619	25,387	705,148	55.88	2.01	27.78
2002	11,923	23,376	673,684	56.50	1.96	28.82
2003	14,113	27,713	821,801	58.23	1.96	29.65
2004	51,954	109,741	3,171,396	61.04	2.11	28.90
2005	60,009	128,096	3,693,458	61.55	2.13	28.83
2006	57,836	123,290	3,617,990	62.56	2.13	29.35
2007	49,262	101,895	3,072,753	62.38	2.07	30.16
2008	70,067	138,693	4,425,889	63.17	1.98	31.91
2009	81,681	152,634	5,043,666	61.75	1.87	33.04
2010	75,852	135,827	4,628,131	61.02	1.79	34.07
<b>Voriconazole</b>						
2000	0	0	0	---	---	---
2001	0	0	0	---	---	---
2002	48	102	2,462	51.29	2.13	24.14
2003	178	570	13,989	78.59	3.20	24.54
2004	488	1,402	34,056	69.79	2.87	24.29
2005	651	1,745	42,330	65.02	2.68	24.26
2006	754	1,951	48,511	64.34	2.59	24.86
2007	1,047	2,663	68,604	65.52	2.54	25.76
2008	1,519	4,068	99,034	65.20	2.68	24.34
2009	1,416	3,955	102,425	72.33	2.79	25.90
2010	1,400	3,671	100,157	71.54	2.62	27.28